Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study

Abstract Background ABO blood group incompatibility between donor and recipient is associated with a number of immunohematological complications, but is not considered a major contraindication to allogeneic hematopoietic stem cell transplantation. However, available evidence from the literature seems to be conflicting as to the impact of incompatibility on overall survival, event-free survival, transplant-related mortality, graft-versus-host disease, and time to neutrophil and platelet engraftment. Methods This single-center, prospective, cohort study included patients with hematological malignancies who underwent a first allogeneic hematopoietic stem cell transplantation between 2008 and 2014. Patients receiving umbilical cord blood as the stem cell source were excluded from this analysis. The impact of ABO incompatibility was evaluated in respect to overall survival, event-free survival, transplant-related mortality, acute graft-versus-host disease and engraftment. Results A total of 130 patients were included of whom 78 (60%) were males. The median age at transplant was 36 (range: 2–65) years, 44 (33%) presented ABO incompatibility, 75 (58%) had acute leukemia, 111 (85%) had a related donor, 100 (77%) received peripheral blood hematopoietic stem cells as graft source and 99 (76%) underwent a myeloablative conditioning regimen. There was no statistically significant association between ABO incompatibility and overall survival, event-free survival, transplant-related mortality, grade II–IV acute graft-versus-host disease, neutrophil or platelet engraftment in multivariate analysis. Conclusion These results show that ABO incompatibility does not seem to influence these parameters in patients undergoing allogeneic hematopoietic stem cell transplantation.

Saved in:
Bibliographic Details
Main Authors: Soares Júnior,José Alfreu, Martinho,Glaucia Helena, Macedo,Antonio Vaz de, Verçosa,Marisa Ribeiro, Nobre,Vandack, Teixeira,Gustavo Machado
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) 2019
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792019000100001
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2531-13792019000100001
record_format ojs
spelling oai:scielo:S2531-137920190001000012019-08-07Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort studySoares Júnior,José AlfreuMartinho,Glaucia HelenaMacedo,Antonio Vaz deVerçosa,Marisa RibeiroNobre,VandackTeixeira,Gustavo Machado ABO incompatibility Hematopoietic stem cell transplant Outcomes of bone marrow transplantation Abstract Background ABO blood group incompatibility between donor and recipient is associated with a number of immunohematological complications, but is not considered a major contraindication to allogeneic hematopoietic stem cell transplantation. However, available evidence from the literature seems to be conflicting as to the impact of incompatibility on overall survival, event-free survival, transplant-related mortality, graft-versus-host disease, and time to neutrophil and platelet engraftment. Methods This single-center, prospective, cohort study included patients with hematological malignancies who underwent a first allogeneic hematopoietic stem cell transplantation between 2008 and 2014. Patients receiving umbilical cord blood as the stem cell source were excluded from this analysis. The impact of ABO incompatibility was evaluated in respect to overall survival, event-free survival, transplant-related mortality, acute graft-versus-host disease and engraftment. Results A total of 130 patients were included of whom 78 (60%) were males. The median age at transplant was 36 (range: 2–65) years, 44 (33%) presented ABO incompatibility, 75 (58%) had acute leukemia, 111 (85%) had a related donor, 100 (77%) received peripheral blood hematopoietic stem cells as graft source and 99 (76%) underwent a myeloablative conditioning regimen. There was no statistically significant association between ABO incompatibility and overall survival, event-free survival, transplant-related mortality, grade II–IV acute graft-versus-host disease, neutrophil or platelet engraftment in multivariate analysis. Conclusion These results show that ABO incompatibility does not seem to influence these parameters in patients undergoing allogeneic hematopoietic stem cell transplantation.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)Hematology, Transfusion and Cell Therapy v.41 n.1 20192019-03-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792019000100001en10.1016/j.htct.2018.05.007
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Soares Júnior,José Alfreu
Martinho,Glaucia Helena
Macedo,Antonio Vaz de
Verçosa,Marisa Ribeiro
Nobre,Vandack
Teixeira,Gustavo Machado
spellingShingle Soares Júnior,José Alfreu
Martinho,Glaucia Helena
Macedo,Antonio Vaz de
Verçosa,Marisa Ribeiro
Nobre,Vandack
Teixeira,Gustavo Machado
Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
author_facet Soares Júnior,José Alfreu
Martinho,Glaucia Helena
Macedo,Antonio Vaz de
Verçosa,Marisa Ribeiro
Nobre,Vandack
Teixeira,Gustavo Machado
author_sort Soares Júnior,José Alfreu
title Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_short Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_full Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_fullStr Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_full_unstemmed Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
title_sort assessing the impact of abo incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study
description Abstract Background ABO blood group incompatibility between donor and recipient is associated with a number of immunohematological complications, but is not considered a major contraindication to allogeneic hematopoietic stem cell transplantation. However, available evidence from the literature seems to be conflicting as to the impact of incompatibility on overall survival, event-free survival, transplant-related mortality, graft-versus-host disease, and time to neutrophil and platelet engraftment. Methods This single-center, prospective, cohort study included patients with hematological malignancies who underwent a first allogeneic hematopoietic stem cell transplantation between 2008 and 2014. Patients receiving umbilical cord blood as the stem cell source were excluded from this analysis. The impact of ABO incompatibility was evaluated in respect to overall survival, event-free survival, transplant-related mortality, acute graft-versus-host disease and engraftment. Results A total of 130 patients were included of whom 78 (60%) were males. The median age at transplant was 36 (range: 2–65) years, 44 (33%) presented ABO incompatibility, 75 (58%) had acute leukemia, 111 (85%) had a related donor, 100 (77%) received peripheral blood hematopoietic stem cells as graft source and 99 (76%) underwent a myeloablative conditioning regimen. There was no statistically significant association between ABO incompatibility and overall survival, event-free survival, transplant-related mortality, grade II–IV acute graft-versus-host disease, neutrophil or platelet engraftment in multivariate analysis. Conclusion These results show that ABO incompatibility does not seem to influence these parameters in patients undergoing allogeneic hematopoietic stem cell transplantation.
publisher Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
publishDate 2019
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792019000100001
work_keys_str_mv AT soaresjuniorjosealfreu assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT martinhoglauciahelena assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT macedoantoniovazde assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT vercosamarisaribeiro assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT nobrevandack assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
AT teixeiragustavomachado assessingtheimpactofaboincompatibilityonmajorallogeneichematopoieticstemcelltransplantoutcomesaprospectivesinglecentercohortstudy
_version_ 1756442044899786752